Pidotimod
Immune & Anti-InflammatoryAlso known as: 3-L-Pyroglutamyl-L-Thiaziolidine-4-Carboxylic Acid, Piglet, Pidotimod Oral
Mechanism
Pidotimod is a synthetic dipeptide immunostimulant approved in several European and Asian countries to reduce the frequency and severity of respiratory infections, particularly in children and elderly patients. It works by stimulating both innate and adaptive immunity — activating dendritic cells to better recognize pathogens, promoting Th1 immune responses, and enhancing the maturation and activity of T-cells. Clinical trials show it can reduce the number of respiratory infections per year by 40-50% when used preventively.
Technical detail
Pidotimod (3-L-pyroglutamyl-L-thiazolidine-4-carboxylic acid) is a synthetic dipeptide immunomodulator acting primarily on dendritic cells (DCs). Mechanism: (1) Upregulates DC maturation markers (CD83, CD86, HLA-DR), enhancing antigen presentation capacity; (2) Stimulates DC production of IL-12 and IFN-α, driving Th1 polarization; (3) Enhances T-cell proliferation and IL-2 production; (4) Increases NK cell cytotoxicity; (5) Upregulates TLR2 and TLR4 expression on innate immune cells, improving pathogen recognition; (6) Stimulates phagocytic activity of macrophages. Meta-analysis of 29 RCTs (Niu et al., 2019) in pediatric recurrent respiratory infections: significantly reduced infection episodes (RR 0.59), antibiotic use, and symptom duration. Oral bioavailability ~45%. Well-tolerated safety profile across pediatric and geriatric populations.
Evidence
- moderate
Deglurkar R, Mathew JL, Singh M. (2022) — Indian Pediatrics — PMID: 35014615
In 79 children with persistent asthma receiving inhaled budesonide, adjunctive pidotimod did not improve peak expiratory flow or symptom control versus placebo over 12 weeks, and no significant adverse effects were observed.
- moderate
Efficacy and safety of pidotimod in the treatment of recurrent respiratory infections in children.
Caramia G, Clemente E, Solli R, Mei V, Cera R, Carnelli V. (1994) — Arzneimittelforschung — PMID: 7857347
In 120 pediatric patients with recurrent respiratory infections, pidotimod was associated with faster recovery, reduced relapse risk, reduced hospitalization, and reduced antibiotic use versus placebo, with no serious safety issues reported.